THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

sAPP and sAPP increase structural complexity and E/I input ratio in primary hippocampal neurons and alter Cahomeostasis and CREB1-signaling

Citation for published version:

Hesse, R, von Einem, B, Wagner, F, Bott, P, Schwanzar, D, Jackson, RJ, Föhr, KJ, Lausser, L, Kroker, KS, Proepper, C, Walther, P, Kestler, HA, Spires-Jones, TL, Boeckers, T, Rosenbrock, H & von Arnim, CAF 2018, 'sAPP and sAPP increase structural complexity and E/I input ratio in primary hippocampal neurons and alter Cahomeostasis and CREB1-signaling', *Experimental neurology*, vol. 304, pp. 1-13.
<https://doi.org/10.1016/j.expneurol.2018.02.010>

Digital Object Identifier (DOI):

[10.1016/j.expneurol.2018.02.010](https://doi.org/10.1016/j.expneurol.2018.02.010)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Experimental neurology

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

**sAPP β and sAPP α increase structural complexity and E/I input
ratio in primary hippocampal neurons and alter Ca²⁺ homeostasis
and CREB1-signaling**

Authors: Raphael Hesse¹, Björn von Einem¹, Franziska Wagner¹, Patricia Bott¹, Daniel Schwanzar¹,
Rosemary J. Jackson⁵, Karl Josef Föhr⁸, Ludwig Lausser⁶, Katja S. Kroker³, Christian Proepper⁴, Paul
Walther⁷, Hans A. Kestler⁶, Tara L. Spires-Jones⁵, Tobias Boeckers⁴, Holger Rosenbrock², Christine
A.F. von Arnim^{*1}

¹Department of Neurology, Ulm University, Ulm, Germany

²Boehringer Ingelheim Pharma GmbH & Co KG, Dept. of CNS Diseases Research, Biberach,
Germany

³Boehringer Ingelheim Pharma GmbH & Co KG, Dept. of Drug Discovery Sciences, Biberach,
Germany

⁴Institute for Anatomy and Cell Biology, Ulm University, Ulm, Germany

⁵UK Dementia Research Institute, The University of Edinburgh, Edinburgh, UK

⁶Institute of Medical Systems Biology, Ulm University, Ulm, Germany

⁷Central Facility for Electron Microscopy, Ulm University, Ulm, Germany

⁸Department of Anesthesiology, Ulm University, Ulm, Germany

*Corresponding author

Christine A.F. von Arnim, MD

Department of Neurology

Oberer Eselsberg 45

89081 Ulm

phone: +49-731-500-63015

fax: +49-731-500-63011

E-mail: christine.arnim@uni-ulm.de (CAFvA)

Abstract

One major pathophysiological hallmark of Alzheimer's disease (AD) is senile plaques composed of amyloid β ($A\beta$). In the amyloidogenic pathway, cleavage of the amyloid precursor protein (APP) is shifted towards $A\beta$ production and soluble APP β (sAPP β) levels. $A\beta$ is known to impair synaptic function; however, much less is known about the physiological functions of sAPP β . The neurotrophic properties of sAPP α , derived from the non-amyloidogenic pathway of APP cleavage, are well-established, whereas only a few, conflicting studies on sAPP β exist. The intracellular pathways of sAPP β are largely unknown. Since sAPP β is generated alongside $A\beta$ by β -secretase (BACE1) cleavage, we tested the hypothesis that sAPP β effects differ from sAPP α effects as a neurotrophic factor. We therefore performed a head-to-head comparison of both mammalian recombinant peptides in developing primary hippocampal neurons (PHN). We found that sAPP α significantly increases axon length ($p = 0.0002$) and that both sAPP α and sAPP β increase neurite number ($p < 0.0001$) of PHN at 7 days in culture (DIV7) but not at DIV4. Moreover, both sAPP α - and sAPP β -treated neurons showed a higher neuritic complexity in Sholl analysis. The number of glutamatergic synapses ($p < 0.0001$), as well as layer thickness of postsynaptic densities (PSDs), were significantly increased, and GABAergic synapses decreased upon sAPP overexpression in PHN. Furthermore, we showed that sAPP α enhances ERK and CREB1 phosphorylation upon glutamate stimulation at DIV7, but not DIV4 or DIV14. These neurotrophic effects are further associated with increased glutamate sensitivity and CREB1-signaling. Finally, we found that sAPP α levels are significantly reduced in brain homogenates of AD patients compared to control subjects. Taken together, our data indicate critical stage-dependent roles of sAPPs in the developing glutamatergic system *in vitro*, which might help to understand deleterious consequences of altered APP shedding in AD patients, beyond $A\beta$ pathophysiology.

Keywords: sAPP, AD, neuronal plasticity, neurodevelopment, CREB-1 signaling

Research highlights:

- sAPP α and sAPP β have a critical stage-dependent role in the developing glutamatergic system *in vitro*
- sAPP β impacts in a different manner on the developing glutamatergic system compared to sAPP α
- Effects of sAPP α are associated with CREB-1 signaling

List of abbreviations:

A β , amyloid β ; AD, Alzheimer's disease; ADAM, A Disintegrin And Metalloproteinase (α -secretase); APP, amyloid precursor protein; AMPA-R, α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; BACE, β -site of APP cleavage enzyme (β -secretase); BDNF, brain-derived neurotrophic factor; CNS, central nervous system; CREB, cAMP-response element binding protein; CSF, cerebrospinal fluid; DIV, days in vitro; EGFP, enhanced green fluorescent protein; GABA, γ -Aminobutyric acid; HRP, horse-radish peroxidase; LOAD, late-onset Alzheimer's disease; LSM, laser-scanning-microscope; LTP, long-term potentiation; NMDA-R, *N*-methyl-D-aspartate receptor; PCR, polymerase chain reaction; PHN, primary hippocampal neuron; PSD, postsynaptic density; sAPP, soluble amyloid precursor protein; TEM, transmission electron microscopy

Introduction

Besides being a central molecule in Alzheimer's disease (AD) pathophysiology, amyloid precursor protein (APP) and its cleavage products are known to be major players in establishing and maintaining neuronal architecture (Nicolas and Hassan, 2014). Depending on whether α - or β -secretase (BACE1) cleaves first, subsequent APP cleavage by γ -secretase fosters or precludes the generation of the neurotoxic amyloid β (A β) fragment (Prox et al., 2012). Alongside failure of A β clearance mechanisms and missense mutations in presenilin 1 or 2 genes, a shift in proteolytic APP processing towards BACE1 cleavage in AD patients that leads to gradually rising A β 42 levels in the brain and therefore causing neuronal death is a well described hypothesis (Selkoe and Hardy, 2016). Besides the increased A β 42 and soluble APP β (sAPP β) production, less sAPP α is also generated.

In contrast to the deleterious effects of A β on neurons, the soluble APP α cleavage product (sAPP α) is known to have neurotrophic or synaptic plasticity enhancing characteristics, as shown by increase of long-term potentiation (LTP) (Taylor et al., 2008). sAPP α , but also sAPP β levels seem to be decreased in cerebrospinal fluid (CSF) of AD patients (Colciaghi et al., 2004; Hock et al., 1998; Lannfelt et al., 1995). BACE1 inhibition, which is a potential disease-modifying therapy for AD, leads to decreased sAPP β levels in the CSF of treated subjects (Kennedy et al., 2016). Interestingly, a missense mutation within the gene encoding for the major α -secretase, ADAM10, resulting in attenuated activity has been recently associated with late-onset AD (LOAD) (Suh et al., 2013). Both findings can therefore lead to an imbalance of soluble APP cleavage products in the central nervous system (CNS). Until now, it has not been known how APP influences neural development and adult brain function or whether loss of these functions can account for AD pathophysiology. Hence, deciphering the physiological functions of both sAPP forms is of crucial importance.

In neuronal cell culture, it has been shown that sAPP α interacts with the p75 neurotrophin receptor to stimulate neurite outgrowth (Hasebe et al., 2013). Furthermore, sAPP α and sAPP β decrease cell adhesion and thereby decrease dendrite outgrowth and increase axon outgrowth (Chasseigneaux et al., 2011). Neuroprotective effects are also described for sAPP α as it could be shown that it protects hippocampal neurons against A β induced oxidative injury (Goodman and Mattson, 1994) and proteasomal stress (Copanaki et al., 2010). Moreover, sAPP α has been shown to extenuate established synaptic and cognitive deficits in the APP/PS1 Δ E9 AD mouse model (Fol et al., 2015). Another study generated a sAPP α -knock-in mouse to show that sAPP α is sufficient to rescue the abnormalities of APP-deficient mice, including reductions in brain weight and the impairment in spatial learning and LTP (Ring et al., 2007). Conversely, there is

one study published demonstrating that cleavage of sAPP β under trophic-factor deprivation generates a cleavage product that is able to induce death receptor 6 signaling and thereby lead to cellular self-destruction (Nikolaev et al., 2009).

Generally, effects of sAPP α on neurons are well established, whereas much less is known about sAPP β function (Chasseigneaux and Allinquant, 2012). In addition, the intracellular pathways mediating the sAPP functions are also largely unknown. Since sAPP β derives from amyloidogenic APP cleavage, we hypothesize that sAPP β opposes neurotrophic sAPP α effects. Therefore, to further evaluate the roles of both sAPPs in neuronal development, we performed in this study a head-to-head comparison in developing primary hippocampal neurons at different time stages.

Materials and Methods

Synthesis of recombinant sAPP peptides

sAPP α and sAPP β gene fragments were amplified by PCR with human APP695 cDNA as template. sAPPs were then N-terminally tagged with the APP secretory sequence, 8x histidine tag, and EGFP. Constructs were subcloned in pcDNATM5/FRT (Invitrogen, Carlsbad, CA, USA) vector by NheI and ApaI restriction sites. The same construct (empty EGFP vector), without sAPP sequence (APP secretory sequence, 8x histidine tag, and EGFP), was used as a control peptide. For purification of sAPP and control proteins, Flp-InTMHEK293 cells were stably transfected (Flp-InTM system, Invitrogen, Carlsbad, CA, USA) with sAPP α , sAPP β and the EGFP construct. Ni-NTA charged agarose beads (Qiagen Hilden, Germany, #30210) were added to the supernatant of the cultivated cells containing the his-tagged sAPP/EGFP fusion proteins. After overnight binding, beads were washed three times with low imidazol buffer (40 mM imidazol) and sAPP/EGFP fusion proteins were subsequently eluted in high imidazol buffer (150 mM imidazol). For buffer exchange and protein concentration eluates were pooled and concentrated via 100 kDa cut-off columns (Millipore Darmstadt, Germany, #UFC810024). Proteins were recovered in PBS and analyzed qualitatively and quantitatively via SDS-PAGE, Western blot, BCA assay, and SimplyBlueTM SafeStain (Invitrogen, Carlsbad, CA, USA) (Fig. S1).

Lentiviral plasmid design and vector production

To generate infectious lentiviral particles, sequences of sAPP α and sAPP β were cloned into pUltra Hot vector. sAPP α and sAPP β gene fragments were amplified by PCR with the above-mentioned sAPP α/β pcDNATM5/FRT as template and inserted into pUltra Hot vector by AgeI and NheI restriction sites. The expressed proteins were N-terminal fusion proteins with mCherry. pUltra Hot is a lentiviral vector backbone for bi-cistronic expression of the gene of interest and the fluorescent reporter mCherry under the control of a human ubiquitin promoter. pUltra Hot was a gift from Malcolm Moore (Addgene plasmid # 24130) and served as a control plasmid to induce viral stress on neurons. psPAX2 is a packaging plasmid encoding HIV-1 gag/pol sequences under the control of a SV40 promoter. psPAX2 was a gift from Didier Trono (Addgene plasmid # 12260). pMD2.G is an envelope-expressing plasmid encoding for VSV-G glycoprotein under the control of a CMV promoter. pMD2.G was a gift from Didier Trono (Addgene plasmid # 12259). For the virus production, LentiX 293T cells (Takara Clontech, Mountain View, CA, USA) were co-transfected (calcium phosphate transfection method) with pUltra Hot, psPAX2 and pMD2.G. Six hours after transfection, the medium was changed to remove transfection reagent in the conditioned medium to which the virus is secreted. 48h after

transfection conditioned medium was collected and filtered using a 0.2 µm sterile filter (Sarstedt, Nuembrecht, Germany). Conditioned medium was transferred to 38.5 ml Beckman Ultra-ClearTM tubes containing 3 ml 20% sucrose and spinned for 2.5 h at 4°C and 24,000 rpm in a Beckman SW32Ti swinging bucket rotor. Supernatant was discarded and virus was resuspended in DPBS, aliquoted and stored at -20°C until use.

Preparation of primary hippocampal neurons

Primary hippocampal neurons were prepared from brains of C57BL/6 embryonic mice (E18), as described previously (Kaeck and Banker, 2006). Briefly, hippocampi were dissected from embryonic brains, the meninges were removed and the cells were dissociated by trypsinization (0.25%) for 20 min at 37 °C. The dissociated cells were resuspended in serum-free neurobasal medium (Gibco®, Invitrogen, Germany) supplemented with 10% B27 (Gibco®, Invitrogen, Germany) and 0.5 mM l-glutamine and seeded into poly-l-lysine-coated culture dishes at a density of 2.2×10^4 cells per cm² for immunocytochemistry (grown on coverslips) and 6.6×10^4 cells per cm² for cell lysis. After 45 min, medium was replaced completely by the same medium, to reduce astroglial growth. Cells were maintained at 37°C in the presence of 5% CO₂ and 10% O₂ in a humidified incubator.

Morphometric analysis of PHN

For morphometric analyzes of PHN, neurons were treated on DIV2 with 100 nM His-EGFP-sAPP α/β or the His-EGFP control peptide, fixed on DIV7 and stained with anti-MAP2 and anti-tau (For antibody specification see list below). To make sure that a substantial amount of sAPPs remains in the culture medium, we used 100nM His-EGFP-sAPP peptide to study long-term effects on neuronal culture. This concentration was previously tested by other groups in similar studies (Chasseigneaux et al., 2011). PHNs were fixed for 20 min in a 4% PFA solution in DPBS. Cells were then washed three times with PBS and subsequently permeabilized and blocked in Roti®-ImmunoBlock (Carl Roth, Karlsruhe, Germany) and 0.3% TritonX-100 for 1 h at RT. Incubation with primary antibodies was performed overnight at 4°C with gentle shaking. The next day, cells were washed three times for 10 min with PBS. Incubation with secondary antibodies was performed for 1 h at RT with gentle shaking. Then cells were washed three times for 10 min with DPBS and embedded in Mowiol® 4-88 plus DABCO. To determine primary axon length, entire neurite length and neurite number, TIFF images of stained neurons were analyzed by ImageJ pluginsoftware NeuronJ. The longest tau positive neurite was considered as the primary axon in DIV7 neurons and the longest beta-III-tubulin neurite was

considered as the primary axon in DIV4 neurons respectively. Sholl analysis (SHOLL, 1953) was performed semi-automatically using ImageJ plugin software Concentric Circles. Briefly, a series of concentric circles was drawn around the soma with 20 μ m between each circle. The number of intersections were counted manually and plotted against the distance from the soma. 180 neurons from three independent cultures were sampled for DIV4 and DIV7 respectively.

Determination of inhibitory and excitatory synapse number

To determine synapse number, PHNs were fixed and stained at DIV14 using the same procedure as described in Morphometric analysis of PHN in the Materials & Methods section. Earlier time points were not suitable for synapse number determination due to immaturity of neurons. Cells were labelled with the primary antibodies anti-Homer1 as postsynaptic marker (SynapticSystems, Göttingen, Germany, #160003), anti-Bassoon as presynaptic marker (Enzo Lifesciences, Lörrach, Germany, #VAM-PS003) and anti-MAP2 as dendritic marker (EnCor Biotechnology, Gainesville, USA, #CPCA-MAP2) upon lentiviral mCherry-sAPP overexpression (DIV2 transduction). The transduction efficiency was about 95% (data not shown). As sAPP-peptides were secreted into the supernatant upon lentiviral overexpression, untransduced neurons were also used for quantification. Colocalization of both synaptic markers along the neurite indicate a mature glutamatergic synapse. All of these are well established synapse and neurite markers used for similar assays (Goetz et al., 2006; Grabrucker et al., 2011; Wang et al., 2016). Confocal images of immunostained neuronal cultures were acquired with a magnification of 63x (water immersion objective, pinhole aperture 1 μ m) by using a Zeiss LSM 710 Meta laser scanning microscope (Carl Zeiss, Jena, Germany), as described previously (Beyer et al., 2012). Quantification was performed semi-automatically by using ZEN blue edition (Zeiss, Oberkochen, Germany). The criteria for determining colocalization was an overlap of intensity peaks of homer1 and bassoon immunofluorescence staining. The counts of glutamatergic inputs were normalized to 10 μ m dendrite length (MAP2 staining) and are indicated as numbers in the results section.

Western blot analysis

Before lysis, neurons pre-incubated with His-EGFP-sAPP were briefly stimulated with 10 μ M glutamate in wash buffer (for buffer composition see FLIPR-analysis part in Material & Methods section) for 30 s. After an additional 3 min in wash buffer, cells were lysed in brain-extraction buffer (BEX: 25 mM Tris pH 8.0, 20 mM NaCl, 0.6% desoxycholate, 0.6 % Igepal CA-630). Cell lysates (10-20 μ g total protein, determined by BCA assay) were separated by

lithium dodecyl sulphate (LDS)-polyacrylamide gel electrophoresis (NuPage Novex Bis-Tris 4-12% gradient gels, Invitrogen) prior to electrophoretic transfer onto 0.2 μ m pore size nitrocellulose membrane (GE Healthcare, Boston, USA, #10600001). The membranes were blocked with 5% non-fat dry milk for 1 h at room temperature. Overnight incubation at 4°C was performed for primary antibody binding (for used antibodies see below). The next day, blots were incubated for 1 h at room temperature with horseradish peroxidase-conjugated secondary antibodies prior to exposure to ECL Luminata Forte (Millipore, Darmstadt, Germany, #WBLUF0100). For detection of the corresponding non-phosphorylated proteins, blots were stripped with 0.1 M glycine, 1% SDS, 1% Tween-20 (pH 3.5) for 15 min at 37°C, followed by blocking in 5% non-fat dry milk and incubated with the antibodies corresponding to the total proteins as described above. Digitized images of the immunoblots were used for densitometric measurements with ImageJ. Relative levels of phosphorylated proteins were determined by normalization of the density of images from phosphorylated proteins with that of the total proteins on the same blot.

Antibodies

The following antibodies were purchased from commercial suppliers: Western blot: anti-phospho-CREB Ser¹³³ (Cell Signaling Technology, clone 8763, #9198) (1:1,000), anti-phospho-p44/p42 MAPK (ERK1/2) Thr²⁰²/Tyr²⁰⁴ (Cell Signaling Technology, clone E10, #9106) (1:1,000), anti-CREB (Cell Signaling Technology, clone 86B10, #9104) (1:1,000), anti-p44/p42 (ERK1/2) (Cell Signaling Technology, clone 86B10, #9104) (1:1,000), anti-beta III Tubulin (Abcam, #ab18207) (1:1,000). Immunocytochemistry (ICC): anti-VGlu1 (SynapticSystems, #135304) (1:400), anti-VGAT (SynapticSystems, #131011) (1:400), anti-Gephyrin (SynapticSystems, #147011) (1:400), anti-Homer1 (SynapticSystems, #160003) (1:500), anti-Bassoon (Enzo Lifesciences, #VAM-PS003) (1:500), anti-MAP2 (EnCor Biotechnology, #CPCA-MAP2) (1:500), anti-beta III Tubulin (Neuromics, #MO15013) (1:500), anti-GAPDH (abcam, #ab9485). Western blot human samples: anti-human sAPP α (IBL International, clone 2B3, #11088), anti-human sAPP β (IBL International, #18957). Secondary antibodies used for Western blot were HRP goat anti-mouse IgG (H+L) and HRP goat anti-rabbit IgG (H+L) (Invitrogen, 1:10,000). Secondary antibodies used for ICC were Alexa Fluor® 488/546/647 Goat anti-Rabbit/Mouse/Chicken IgG (H+L) (Invitrogen, 1:750).

Electron-microscopical investigations

Neurons were plated with a density of 6.6×10^4 cells per cm^2 . After 14 days in culture, neurons were fixed with 2.5% glutaraldehyde in 0.1 M phosphate buffer with 1% sucrose (pH 7.3) and postfixed with 1% osmium tetroxide for 4 h. Cultures were then dehydrated through an increasing propanol series, stained with 2% uranyl acetate and embedded in epoxy resin (Epon 812, Fluka, Germany). Ultrathin sections (70–80 nm) were cut with a diamond knife on a Reichert ultramicrotome and collected on 300- mesh grids. The sections were stained with lead citrate and examined at a voltage of 100 kV by using the transmission electron microscope JEM-1400 (Jeol, Akishima, Japan). Images were recorded with a resolution of $2,048 \times 2,048$ pixels and a magnification of 50,000x using a Veleta digital camera (Olympus Soft Imaging Solutions GmbH, Münster, Germany) and the iTEM software (Olympus Soft Imaging Solutions GmbH, Münster, Germany). At least 20 images of PSDs from asymmetric synapses in different cells were acquired per condition and independent experiment. Single images of the synapse were taken to measure PSD thickness. The thickness was determined manually by using ImageJ to measure the thickness from electron dense areas at three different locations in each PSD (central, and left/right from the centre, orthogonal to the PSD). The three measured values were averaged and defined as PSD thickness for the measured synapse.

FLIPR-analysis

Intracellular Ca^{2+} changes were monitored using the FLIPRTetra fluorometric imaging plate reader (Molecular Devices, CA, USA). Before dyeloading, Neurobasal culture medium was removed. The neurons were washed three times with imaging buffer (NaCl 145 mM, KCl 5 mM, CaCl_2 2 mM, Glucose 25 mM, HEPES 12 mM, pH was adjusted to 7.4). After the last wash step, neurons were loaded with 2 μM Fluo-4 diluted in imaging buffer. Neurons were incubated for 45 min at 37°C. Then, neurons were washed three times with 180 μl imaging buffer left after the last wash step. Neurons were incubated for 15 min with 1nM His-EGFP-sAPP α , His-EGFP-sAPP β or the control peptide His-EGFP. We decided to use 1 nM of both sAPP forms and control peptide in the FLIPR experiments, since this concentration (concentration response curve with 0.01, 0.1, 1 and 10 nM) was previously tested by other groups in similar studies on Ca^{2+} mobilization (Furukawa et al., 1996a; Furukawa and Mattson, 1998). Regarding long-term studies, to make sure that a substantial amount of sAPPs remains in the culture medium over the time course of the experiment, we used the supra-effective concentration of 100nM sAPP peptide to the study long-term effects of sAPPs on neuronal culture. This experiment was not aimed at defining exactly the minimal effective concentration, but rather to investigate mechanistically the long-term effects of sAPPs. Further, this

concentration was previously tested successfully by other groups in similar experiments (Chasseigneaux et al., 2011). After recording the baseline for 10 s, 20 μ l imaging buffer containing 100 μ M glutamate (final concentration in wells was 10 μ M) was added to the wells and the kinetic of the Ca^{2+} responses was measured on the FLIPR device for evaluation of intrinsic compound activity.

Synaptoneurosome preparation

Synaptoneurosomes and homogenates were prepared as described in Tai et al. 2012 (Tai et al., 2012) using human end stage AD and control brain tissue provided by the Edinburgh Brain Bank. In brief, approximately 300 mg of Brodmann area 41/42 was homogenized in 1 ml of ice cold Buffer A (25 mM HEPES pH 7.5, 120 mM NaCl, 5 mM KCl, 1 mM MgCl_2 , and 2 mM CaCl_2), supplemented with 2 mM dithiothreitol (DTT), protease inhibitors (roche complete mini) and phosphatase inhibitors (Millipore, 524629). The homogenate was filtered through 2 layers of 80 μ m nylon filter (NY8002500, Millipore), and a 200 μ l aliquot of this was saved as the crude homogenate. The saved aliquot was mixed with 140 μ l water, 60 μ l of 10% SDS and boiled for 5 minutes. To prepare the synaptoneurosomes the remainder of the homogenate was filtered through a 5 μ m filter (SLSV025NB, Millipore) and centrifuged at 1,000 g for 5 minutes. The supernatant was removed and the pellet was suspended in Buffer A and centrifuged again (1,000 g for 5 min). The supernatant was again removed and the resulting synaptoneurosome pellet was suspended in 400 μ l of Buffer B (50 mM Tris [pH 7.5], 1.5% SDS, and 2 mM DTT) and boiled for 5 min.

Protein concentration was determined using a BSA assay (ThermoFisher, 23225) and 5 mg of protein from either synaptoneurosome or crude homogenate was loaded onto NuPAGE 4-12% Bis-Tris precast polyacrylamide 15 well gels (Invitrogen, Paisley, UK) along with molecular weight marker (Li-Cor, Cambridge, UK). Proteins were electro-transferred to nitrocellulose membrane (Bio-Rad, Hemel Hempstead, UK). Membranes were blocked using Odyssey Blocking Buffer (927-40000, LI-COR) diluted 1:1 in PBS. Primary antibodies were incubated overnight in block with gentle shaking. Proteins were visualized on an Odyssey infrared system using the appropriate 680 and 800 IR dye secondary antibodies (1:50,000, LI-COR Biosciences) and were analyzed using Odyssey software (LI-COR Biosciences). Patient demographic data are depicted in Table S1.

Data analysis

All statistical analyzes were carried out by GraphPad Prism 6.05. Data was tested for Gaussian distribution by the D'Agostino-Pearson omnibus normality test. For comparison of two groups, a Students *t*-test was used. When data was not normally distributed, the ranked values of two groups were tested for significant differences using a Mann-Whitney *U*-test. A Kruskal-Wallis test and Dunn's post hoc test for multiple comparisons were used when more than two groups were tested for significant differences. Statistically significant differences in FLIPR analysis among different groups were determined using Two-Way ANOVAs with a Dunnett's post-hoc test for multiple comparisons. The results are expressed as median (25th–75th percentile).

As an integrative analysis over different distances the results of the Sholl analysis were analyzed in comparative regression experiments (Dünkler et al., 2015). A global regression model fitted to the samples of both groups (treated/untreated) was tested against a pair of group-wise models fitted individually to the curves treated or the untreated samples. The significance of a difference between the treated group and the untreated group was determined by a comparison of the least square errors of the global model and the pair of individual models (F-Test) (Lomax et al., 2012; Motulsky and Ransnas, 1987). The model types were selected via the Akaike information criterion (Burnham et al., 2002). They were chosen from a set of 10 predefined model types. The corresponding software (CuCompare) is available at <http://sysbio.uni-ulm.de/soft/CuCompare>.

Results

sAPP treatment of PHN affects neuronal morphology and complexity in a stage-dependent manner

To determine the differential effects of sAPPs on neuronal morphology and branching we produced recombinant proteins of human sAPP α 695 and sAPP β 695 in HEK293 cells. These bear all post-translational modifications observed in eukaryotic cells. PHNs were treated at DIV2 with 100 nM His-EGFP-sAPP α or His-EGFP-sAPP β and fixed and immunostained with MAP-2 and Tau at DIV7 or β -III-tubulin at DIV4 respectively. His-EGFP-sAPP administration (100 nM) to PHN at DIV2 with fixation at DIV 4 did not lead to altered primary axon length (Fig. 1A), entire neurite length (Fig. 1B), and neurite number (Fig. 1C). The median lengths, 25th and 75th percentiles are depicted in table 1.

When PHNs were treated with the same concentration of His-EGFP-sAPP at DIV2 and fixed at DIV7, the median primary axon length was increased significantly by 21.5% upon His-EGFP-sAPP α treatment ($p = 0.0002$) but not upon His-EGFP-sAPP β treatment (Fig. 1 D). Morphometric analysis also revealed a significant increase in median neurite length per neuron ($p < 0.0001$) (Fig. 1E) and also in median neurite number by 50% upon His-EGFP-sAPP α and 33.3% upon His-EGFP-sAPP β treatment ($p < 0.0001$) (Fig. 1F). The median lengths, 25th and 75th percentiles are depicted in table 1. The significant increase in neurite number upon His-EGFP-sAPP α and His-EGFP-sAPP β treatment raised the question if there is also alteration in neuritic ramification. To determine neuritic complexity at DIV7, Sholl analysis was performed. We plotted the number of intersections of neurites with each circle against the distance from the cell body (see scheme in Fig. 1G). This extensive analysis revealed a significant increase in neuritic arborization upon His-EGFP-sAPP α and His-EGFP-sAPP β treatment (Fig. 1H) significant for distances from soma from 20 μ m to 200 μ m, $p < 0.05$). Further analysis revealed a distinct pattern of arborization for His-EGFP-sAPP α and His-EGFP-sAPP β , with increased branching close to the soma for His-EGFP-sAPP α . Exemplary images of analysed neurons are shown in Fig. S2.

Table 1. Summarized morphological analysis of primary hippocampal neurons

	4 DIV ctrl	4 DIV sAPP α	4 DIV sAPP β
Axon length [nm]	113.1 (86.14 – 146.5)	109.3 (77.41 – 139.2)	113.5 (35.19 – 153.8)
Neurite length [nm]	226.2 (182.8 – 268.4)	220.0 (174.3 – 277.6)	242.6 (191.8 – 295.6)

Neurite number	4 (3 – 5)	4 (3 – 5)	4 (3 – 5)
	7 DIV	7 DIV	7 DIV
	control	sAPPα	sAPPβ
Axon length [nm]	324.4 (255.2 – 438.5)	394.1 (322.6 – 470.7)*	352.2 (283.1 – 445.3)
Neurite length [nm]	1234.0 (868.8 – 1680.0)	1696.0 (1430.0 – 2174.0)*	1622.0 (1303.0 – 2095.0)*
Neurite number	12 (9 – 16)	18 (14 – 23)*	16 (12.25 – 22)*

Axon lengths, neurite lengths and neurite numbers are indicated as median (25th-75th percentile). Statistical significance is marked by an asterisk. * $p < 0.0001$, One-Way ANOVA, Kruskal-Wallis test, Dunn's post-hoc test.

Advanced glutamatergic synaptic architecture upon sAPP overexpression

To test the hypothesis that the increased neuritic arborization of PHN upon His-EGFP-sAPP treatment at DIV7 (first mature synapses observed) is associated with an increased function of glutamatergic synapses, we determined the synapse number upon lentiviral sAPP overexpression and compared them with control neurons at DIV14, where synaptic maturation is well established. Use of the lentiviral expression system ensured a stable and brief secretion of sAPP to supernatant of neuronal cell culture from DIV2 to DIV14. Secretion of sAPP peptides to neuronal cell culture supernatant was verified by Western blot (Fig. S1). Using double staining for Homer1 (postsynaptic marker) and Bassoon (presynaptic marker) at DIV 14, we were able to discriminate immature from mature glutamatergic synapses (Grabrucker et al., 2009). Colocalization of Homer1 and Bassoon indicated a fully developed excitatory synapse (Fig. 2A). We observed that 75% more mature glutamatergic synapses were developed until DIV14, when mCherry-sAPP α was overexpressed ($p < 0.0001$) and 25% more mature synapses when mCherry-sAPP β ($p < 0.0001$) was stably secreted for 12 DIV in primary hippocampal neurons. The median number of mature glutamatergic synapses at DIV14 was 1.6 (1.2–2.0) in the control condition, 2.8 (2.1–3.5) upon mCherry-sAPP α overexpression and 2.0 (1.6–2.3) upon mCherry-sAPP β overexpression (Fig. 2B). mCherry-sAPP α as well as mCherry-sAPP β overexpression resulted in a marked rightward shift in the frequency distribution of synapse numbers, indicating an increased number of colocalizations (Fig. 2C).

To test the hypothesis that increased sAPP levels, leading to an increased number of glutamatergic synapses, also lead to alterations in the subsynaptic architecture, we determined PSD layer thickness from asymmetric synapses in mCherry-sAPP-overexpressing neurons by

electron microscopy. Asymmetric synapses were distinguished from symmetric synapses. The former are excitatory in function and are formed by axon terminals that contain spherical synaptic vesicles and an electron-dense PSD (Fig. 2D, asterisks mark PSDs). We observed that PSDs of neurons exposed to higher extracellular sAPP α levels showed a 27.4% increase in median layer thickness compared to control neurons. PSDs of mCherry-sAPP β -overexpressed neurons were not significantly changed. The median PSD strength of neurons was 14.6 nm (10.5–17.6 nm) in control, 18.6 nm (14.1–23.0 nm) after treatment with mCherry-sAPP α and 14.0 nm (10.9–17.1 nm) after treatment with mCherry-sAPP β (Fig. 2E). Increased exposure to mCherry-sAPP α led to a homogenous rightward shift in frequency distribution of PSD layer thickness (Fig. 2F).

Increased neuritic arborization is associated with higher levels of activated markers of neuronal activity

Since it has been previously described that sAPP levels are altered during aging and disease, we hypothesized that sAPPs can influence neuronal activity of matured PHNs. To test, whether mature hippocampal neurons are responsive to sAPP effects mediated by the glutamatergic system in principal, neurons were loaded with a Ca²⁺-sensitive dye (Fluo4) and incubated for 15 min with 1 nM of His-EGFP control peptide, His-EGFP-sAPP α or His-EGFP-sAPP β at DIV14. Subsequent Ca²⁺-imaging by a FLIPR system revealed that both His-EGFP-sAPP α and His-EGFP-sAPP β administration increased glutamate (stimulation with 10 μ M glutamate) induced cytoplasmatic Ca²⁺ levels in mature hippocampal neurons (Fig. 3A).

Next we tested whether downstream Ca²⁺ signaling is also affected by long-term application of His-EGFP-sAPP peptides. We administered 100 nM His-EGFP control peptide, His-EGFP-sAPP α or His-EGFP-sAPP β to primary hippocampal neurons at DIV2 (lentiviral mCherry-sAPP overexpression for DIV14 neurons). At DIV4, DIV7 or DIV14, hippocampal neuronal cultures were briefly stimulated with 10 μ M glutamate for 30 s to induce neuronal activity in the glutamatergic system. Subsequent determination of p-ERK2 and p-CREB1 levels revealed that hippocampal cell cultures treated with 100 nM His-EGFP-sAPP α from DIV2 to DIV7 show significantly higher levels of phosphorylated ERK2 (78.4% increase, $p = 0.02$) (Fig. 3B) and CREB1 (300.1% increase, $p = 0.01$) (Fig. 3C) determined by Western blot (normalized to total levels of ERK2 or CREB1 respectively). By contrast, we did not see changes induced by His-EGFP-sAPP administration upon glutamate stimulation of DIV4 or DIV14 neuronal cell

cultures compared to treatment with the His-EGFP control peptide (Fig. 3B, C). To further elucidate the short-term effects of His-EGFP-sAPP α and His-EGFP-sAPP β on the phosphorylation of CREB, SH-SY5Y cells were transfected with a FRET-based CREB1 biosensor (ICAP) and pre-treated with 1nM His-EGFP-sAPP α and His-EGFP-sAPP β . Ratiometric analysis of the FRET fluorophores revealed a significant increase in CREB1 phosphorylation upon His-EGFP-sAPP α treatment 5 mins after glutamate stimulation (Fig. S3 A). CREB1 phosphorylation level was unchanged upon His-EGFP-sAPP β treatment (Fig. S3 B).

sAPP overexpression led to advanced glutamatergic architecture at DIV14 comparable to control treated DIV21 neurons but it suppresses the formation of GABAergic inputs

sAPP effects may be limited to a subpopulation of synaptic terminals. We therefore asked to what extent glutamatergic, as opposed to GABAergic, synaptic terminals benefited from the presence of sAPPs in supernatant of neuronal culture medium. To answer this question, we transduced PHNs at DIV2 with mCherry-sAPP α -, mCherry-sAPP β - or a mCherry-control-lentivirus. At DIV14 and DIV21, we counted VGlut1 positive puncta along the dendrite as markers for the excitatory presynapse (Fig. 4A). VGAT1 was used as a marker for inhibitory synapses (Fig. 4C). Upon mCherry-sAPP α overexpression, DIV14 PHNs showed a significant increase in VGlut1 positive puncta (20%, $p < 0.0001$) normalized to 10 μ m dendrite length compared to overexpression of the mCherry control construct (Fig. 4B). When mCherry-sAPP β was overexpressed in primary neurons until DIV14, the median number of VGlut1 positive puncta was elevated by 20% ($p < 0.0001$). The median quantity of VGlut1 positive puncta at DIV14 was 1.5 (1.2 – 1.7) in the control, 1.8 (1.5–2.1) in the mCherry-sAPP α overexpressing neurons and 1.8 (1.5 – 2.1) upon mCherry-sAPP β overexpression in primary hippocampal neurons.

In contrast to glutamate-releasing presynapses, GABA-releasing terminals are inhibitory in function. To test whether synaptogenesis in general is elevated in the presence of exogenous sAPP, we next determined the number of GABA- versus glutamate-releasing terminals in DIV14 neurons in mCherry-sAPP-overexpressing hippocampal neurons (Fig. 4C). Upon mCherry-sAPP α overexpression, 32% less GABAergic terminals were developed compared to overexpression of the control construct ($p < 0.0001$). The number of GABA-releasing presynapses was also significantly reduced by 28% when developing neurons were exposed to

mCherry-sAPP β compared to the control peptide ($p < 0.0001$) (Fig. 4D). The median of absolute inhibitory presynapses were 1.0 (0.8–1.2) after mCherry-sAPP α , 1.0 (0.8–1.3) after mCherry-sAPP β and 1.4 (1.2–1.7) upon mCherry-control construct overexpression. The calculated ratio of glutamatergic to GABAergic synaptic terminals was significantly increased by 76% upon mCherry-sAPP α and 72% after mCherry-sAPP β overexpression ($p < 0.001$) (Fig. 4E).

To further test the hypothesis that neuronal development *in vitro* is advanced resulting from a neuronal network exposed to elevated sAPP levels, we transduced PHNs at DIV2 with a mCherry-control-lentivirus and counted VGlut1 and VGAT at DIV21 and compared them with DIV14 mCherry-sAPP-overexpressing neurons. We found that neurons overexpressing the control construct from DIV2 to DIV21 showed 27% ($p < 0.0001$) more VGlut1, but no significant change in the number of VGAT positive puncta compared to neurons overexpressing the control construct from DIV2 to DIV14 (Fig. 4B,D). The median count of VGlut1 positive puncta at DIV21 was 1.9 (1.6–2.2) (Fig. 4B) and 1.6 (1.3–1.9) (Fig. 4D) for VGAT positive puncta upon overexpression of the control construct. A proposed model of how sAPP could affect synapse development *in vitro* is depicted in Fig. 4F.

sAPP α is decreased in AD brains and can be detected in human synaptoneurosomes

Since we were able to show that sAPP α and sAPP β have crucial functions in the development of the glutamatergic system *in vitro* and activity of the major α -secretase ADAM10 and BACE1 activity seem to be altered in LOAD patients, we next asked whether sAPP levels are altered in homogenates and synaptoneurosomes of human *post-mortem* tissue of AD patients and control subjects. To do so, we enriched synaptoneurosomes from BA41/42 of end stage brain tissue by a previously reported method (Tai et al., 2012). Western blot analysis with a human sAPP α -specific antibody revealed that sAPP α is significantly decreased by about 53% in brain homogenate of AD patients compared to control subjects (Fig. 5A, $p = 0.007$). We further observed a tendency of reduced sAPP α levels in synaptoneurosomes of AD patients (Fig. 5B, $p = 0.128$). We also tested if sAPP β is detectable in human brains with a human sAPP β specific antibody. We were not able to detect full length sAPP β in human brain homogenates or synaptoneurosomes, but cleavage fragments (Fig. S4). Therefore, we did not quantify these Western blots.

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534 **Discussion**

535 Considering that levels of the soluble APP ectodomains, released by initial ADAM-10 or
536 BACE1 cleavage, are altered in AD patients (Cuchillo-Ibañez et al., 2015; Holsinger et al.,
537 2004; Lannfelt et al., 1995; Palmert et al., 1990; Zetterberg et al., 2008), the natural *in vivo*
538 function of sAPPs in the CNS are of pivotal interest.

539 In this study, we investigated the impact of sAPPs on the glutamatergic system and the
540 accompanying morphological changes in hippocampal neuronal cell culture side by side. We
541 found that both sAPP β and sAPP α stimulate the glutamatergic system in hippocampal neurons
542 *in vitro* and regulate neuronal development and synapse formation in a stage-dependent fashion.

543 Our study reports several important findings. First, both sAPP β and sAPP α affect neuronal
544 morphology and complexity in a stage-dependent manner in PHNs. Having structurally and
545 functionally different processes that act as communication relay in the CNS, neurons are one
546 of the most highly polarized cell types in nature (Takano et al., 2015). As in our study, DIV4
547 PHNs do not show morphological differences when analyzed by determining the axon length,
548 entire neurite length and neurite number. Therefore, sAPPs should not interfere with early
549 stages in neuronal development *in vitro*. The observation that His-EGFP-sAPP β -treated
550 neurons showed different effects in Sholl analysis compared to His-EGFP-sAPP α -treated
551 neurons, suggests that different receptors may be involved in mediating sAPP α and sAPP β
552 effects. Considering that, in our study, sAPPs interfered with intermediate stages (DIV7), but
553 not with early stages (DIV4) of neuronal development in cell culture, we can assume that sAPPs
554 affect dendritic development rather than axon specification. Since we further showed that
555 sAPPs impact on glutamate signaling, it seems likely that functions are mediated by modulation
556 of a subset of distinct glutamate receptors that are differentially expressed during PHN
557 development *in vitro* (Janssens and Lesage, 2001) and *in vivo* (Luján et al., 2005). A recent
558 study by Hasebe et al. revealed that sAPP α promotes neurite outgrowth in stage 1 neurons (24
559 h after plating) (Hasebe et al., 2013). This finding contradicts our results to some extent, but
560 differences might be explained by the use of another neuronal culture system (cortical neurons
561 instead of hippocampal neurons). In fact, in line with our findings, Chasseigneaux et al. were
562 able to demonstrate that sAPP α increases axon length in primary neurons (Chasseigneaux et
563 al., 2011). In contrast to our findings, they observed a decrease in dendrite outgrowth. The
564 difference could be explained by the earlier stage (DIV5 neurons from E16 mice vs. DIV7
565 neurons from E18 mice) they examined or the investigation of cortical neurons instead of
566 hippocampal neurons and the utilization of another mouse strain (Swiss instead of C57BL/6).

Our results are also in agreement with a previous study showing that sAPP α enhances axon growth (Young-Pearse et al., 2008).

Second, in this study, we show that mCherry-sAPP overexpression in PHNs results in increased glutamatergic synaptic architecture in DIV14 neurons. For precise functioning of the mammalian brain, it is crucial that neuronal contacts are formed properly and maintained in the long term, if needed. Since synaptogenesis in PHNs is dependent on neuronal activity and connectivity, amongst others, we next asked whether long-term exposure of sAPPs to PHNs impacts synaptogenesis and the formation of subsynaptic structures like the PSD. In line with our findings, that both mCherry-sAPP α and mCherry-sAPP β overexpression led to a higher number of mature glutamatergic synapses in PHNs, Bell et al. reported that ADAM-10-overexpression in mice increased the brain sAPP α levels and the number of presynaptic bouton densities (Bell et al., 2008). Other work showed that infused sAPP α increased memory retention and synaptic density in the frontoparietal cortex of rats (Roch et al., 1994). The process of synapse formation involves axo-dendritic contact after axon extension, presynaptic and postsynaptic differentiation, synaptic maturation, pruning and maintenance (Johnson-Venkatesh and Umemori, 2010). At which stage sAPPs enhance synaptogenesis is not clear yet and remains to be answered. The observation that mCherry-sAPP α exposure leads to increased layer thickness of PSDs in PHN synapses, agrees with several studies investigating the effects of sAPP α on synaptic transmission and LTP (Taylor et al., 2008) or the ability of sAPP α to rescue synaptic deficits in different APP transgenic mice (Fol et al., 2015; Hick et al., 2015; Ring et al., 2007). Claasen et al. further showed, that sAPP α upregulates synaptic protein synthesis by a proteinkinase G-dependent mechanism in synaptoneurosomes prepared from rat hippocampi (Claasen et al., 2009). Based on these results, we can conclude that the sAPP-induced extended neuritic arborization at DIV7 ends up in an advanced synaptic architecture of glutamatergic synapses at later stages (DIV14) of neuronal development *in vitro*.

Third, we demonstrated that increased neuritic arborization is associated with higher levels of activated markers of neuronal activity. Development of the neuritic arbor and synaptogenesis are, *inter alia*, dependent on neuronal activity. To that end, we tested the hypothesis that the more sophisticated arborization at DIV7 and the advanced synaptic architecture at DIV7 upon sAPP exposure is associated with neuronal activity. We first tested whether sAPPs influence glutamate-evoked Ca²⁺ signals in mature PHNs. By showing that both His-EGFP-sAPP α and His-EGFP-sAPP β (15 min preincubation) increase free intracellular Ca²⁺ levels upon glutamate stimulation, we concluded that sAPPs modulate glutamate sensitivity of PHNs in a short-term

600 response. Given that a 15 min preincubation with sAPPs was enough to alter glutamate
601 sensitivity of PHNs, a mobilization of the synaptic AMPA-R pool mediated by sAPPs is more
602 likely than a transcription-based response. To obtain a more detailed picture of how sAPPs
603 modulate neuronal plasticity on a molecular level, we next asked whether glutamate-activated
604 synaptic plasticity-dependent downstream targets of Ca^{2+} signaling are also affected by His-
605 EGFP-sAPP exposure to neurons. Downstream components of Ca^{2+} are, amongst others,
606 mitogen-activated protein kinase 1 (ERK2) and the transcription factor cyclic AMP-responsive
607 element-binding protein 1 (CREB1). Hence, we tested whether His-EGFP-sAPPs modulate
608 ERK2 and CREB1 phosphorylation in glutamate stimulated PHNs at different stages of
609 development (DIV4, DIV7, DIV14). When PHNs were briefly stimulated with glutamate, we
610 detected increased levels of p-ERK2 as well as p-CREB1 upon long-term His-EGFP-sAPP α
611 exposure to neurons until DIV7. By contrast, we did not see any differences in p-ERK2 or p-
612 CREB1 levels at DIV4 or DIV14 glutamate-stimulated PHNs when exposed to His-EGFP-
613 sAPPs compared to control. We concluded that a peak level of phosphorylated LTP-dependent
614 kinases at DIV7 leads to increased neuritic arborization and subsequently to an advanced
615 development of glutamatergic synapses. Unchanged levels of activated ERK2 and CREB1 at
616 DIV4 upon His-EGFP-sAPP treatment are associated with unaltered neuritic morphology.
617 Long-term His-EGFP-sAPP exposure to neurons did not affect p-ERK2 or p-CREB1 levels
618 when the neuronal network was stimulated at DIV14. The latter could be a ceiling effect or a
619 compensatory mechanism to protect neurons from overexcitation. To determine short term
620 effects of sAPPs, we analyzed time resolution of sAPP treatment immediately after treatment
621 in SH-SY5Y cells. We found an immediate response on CREB1 phosphorylation upon His-
622 EGFP-sAPP α treatment. These results are in line with a study by Ryan et al. showing that
623 sAPP α induces time-dependent changes in gene expression in the rat hippocampus, amongst
624 other downstream targets of CREB1 (Ryan et al., 2013). Our results further confirm recent
625 findings revealing that sAPP α and sAPP β promote Egr1/ERK1 signaling leading to enhanced
626 axon outgrowth *in vitro* (Chasseigneaux et al., 2011). Moreover, a study by Rohe et al. showed
627 that increased levels of sAPP correlated with pro-found stimulation of neuronal ERK signaling
628 (Rohe et al., 2008). Since we have shown that sAPPs modulate glutamate induced CREB1
629 activation, a direct modulation of one or more distinct glutamate receptor seem to be likely.
630 However, which of glutamate receptor (or subunit composition) is modulated by sAPPs remains
631 to be determined. At least, one study by Taylor et al. showed that sAPP α regulates hippocampal
632 NMDA-receptor function (Taylor et al., 2008).

Fourth, mCherry-sAPP overexpression led to advanced glutamatergic architecture at DIV14 comparable to control-treated DIV21 neurons, but it suppresses the formation of GABAergic inputs. Since we showed, that both sAPPs positively regulate neuritic arborization and synapse formation, we determined whether the sAPP effects are a mere mechanism of advanced development. Therefore, we compared the number of inhibitory and excitatory synaptic inputs of mCherry-sAPP-treated PHNs at DIV14 with control treated DIV21 neurons. We found that the number of excitatory synaptic inputs of DIV14 PHNs exposed to mCherry-sAPPs was comparable with control-treated DIV21 neurons. In contrast, the number of inhibitory inputs in hippocampal cell culture was not decreased in the control when comparing DIV21 with DIV14. We show here for the first time that the number of inhibitory synaptic inputs, determined by VGAT immunostaining, is decreased when comparing control treated DIV14 inhibitory inputs with DIV14 mCherry-sAPP-treated inhibitory inputs. Therefore, we concluded that sAPP effects are not merely resulting from advanced neuronal development, but rather modulate the ratio of excitatory to inhibitory inputs. Since proper formation and function of neuronal circuits depends on the balance of inhibitory and excitatory mechanisms, this is an important finding. To rule out that the decrease in GABAergic input is a consequence of cell death, we tested if sAPPs impact on cell viability by the MTT assay. We found no impact of sAPP preparations on cell viability, even at high concentrations (data not shown). Interestingly, genes related to GABAergic signaling like glutamate decarboxylase 1 and 2 (GAD) or somatostatin (Sst) possess CREB1 binding sites in their promotor regions (Zhang et al., 2005). Furthermore, in patients suffering from autism spectrum disorders (ASDs), an imbalance in GABAergic/glutamatergic inputs was observed (El-Ansary and Al-Ayadhi, 2014) and increased levels of sAPP α were described in the CSF of ASD patients (Ray et al., 2011). Whether these findings correlate statistically significantly or are causative for pathophysiology remains to be determined. Our finding that neuronal complexity, synapse maturation and E/I balance are increased in PHNs upon sAPP exposure are in line with several studies focusing on BDNF effects on developing neurons (Ji et al., 2010; Singh et al., 2006). This raises the question of whether sAPP can directly/indirectly modulate or bind to TrkB receptors to induce BDNF-like effects. Further studies are needed to shed light on this hypothesis.

Fifth, in almost all our assays assessing the effects of sAPPs on glutamatergic development, we observed that sAPP β effects are similar to neurotrophic sAPP α effects. These findings disprove our hypothesis that sAPP β differs from the neurotrophic effects on the developing glutamatergic system of sAPP α . Differences between sAPP α and sAPP β were seen in the Sholl analysis that revealed a distinct pattern of ramification for sAPP α and sAPP β , with increased

667 branching close to the soma for sAPP α . In contrast to sAPP α -treated neurons, sAPP β exposure
668 did not lead to axon elongation. Furthermore, sAPP β -treated neurons did not show increased
669 PSD layer thickness or ERK phosphorylation, whereas sAPP α -treated neurons did.
670 Interestingly, a study by Furukawa et al. could show that sAPP α was approximately 100-fold
671 more potent than sAPP β in protecting hippocampal neurons against excitotoxicity, A β toxicity,
672 and glucose deprivation (Furukawa et al., 1996b). The main domains described to mediate the
673 neurotrophic effects of sAPP α are shared by sAPP β , except for the last 16 c-terminal amino
674 acids. This would favor a model where the common parts of sAPP α and sAPP β mediate the
675 observed functions. Other functions might be affected differentially as a study by Peters-Libeu
676 et al. indicated that, despite the large sequence homology between both sAPPs, the folding is
677 different, leading to different effects on APP cleavage by BACE1 (Peters-Libeu et al., 2015).
678 If sAPP α and sAPP β bind (e.g. depending on their folding) to the same or distinct receptors to
679 mediate their functions remains elusive.

680 Finally, we observed that sAPP α is significantly decreased in human AD brains and detectable
681 in human synaptoneurosomes compared to control subjects. Until now, almost all studies
682 investigating the protein levels of sAPPs in human CNS used CSF as sample material
683 (Colciaghi et al., 2004; Hock et al., 1998; Lannfelt et al., 1995; Palmert et al., 1990). We show
684 here for the first time, that sAPP α is significantly decreased in AD brains and abundant in
685 human synaptoneurosomes in AD patients and control subjects. Moreover, we observed a
686 reduction in sAPP levels in human synaptoneurosomes from AD patients compared to control
687 subjects by trend. Both confirmed studies which found decreased sAPP α levels in CSF of AD
688 patients (Colciaghi et al., 2004; Hock et al., 1998; Lannfelt et al., 1995; Palmert et al., 1990).
689 The sAPP β antibody used in our study was not suitable to detect full length sAPP β . For this
690 reason, it remains to be determined if sAPP β is also altered in AD brains. Since we
691 demonstrated several crucial effects of sAPP α and sAPP β in neuronal development, reduced
692 sAPP α levels in brains of AD patients could have deleterious effects beyond A β
693 pathophysiology, e.g. due to decrease of specific neurotrophic or neuroprotective mechanisms.
694 Furthermore, altered sAPP levels in the developing brain might contribute to selective
695 vulnerability of hippocampal neurons and therefore accelerating disease progression, e.g. by
696 interfering with neuronal cell-type specification mechanisms (Götz et al., 2009). Disturbances
697 in adult neurogenesis might be another explanation of how altered sAPP levels can account for
698 AD pathophysiology (Lazarov and Demars, 2012; Lazarov and Marr, 2010; Wang et al., 2014).

Taken together, our study confirmed previous findings describing neurotrophic effects for sAPP α and revealed that human recombinant sAPP β effects resemble sAPP α effects, but to a lesser extent. We further showed that neurotrophic effects of both sAPPs in early PHN development are associated with advanced glutamatergic development and revealed that sAPPs lead to altered E/I balance in mature hippocampal neurons (Fig. 4F). Synaptic impairments observed in AD patients might be a consequence not only of A β accumulation, but also to the loss of synapse-promoting abilities of sAPP α and sAPP β . Our data indicate critical stage-dependent roles of both sAPPs in the developing glutamatergic system *in vitro*, and thus lead to a better understanding of deleterious consequences of altered APP shedding in AD patients and BACE-1 inhibitor recipients.

Acknowledgments

Ethics approval and consent to participate: Use of human tissue for post-mortem studies has been reviewed and approved by the Edinburgh Brain Bank ethics committee and the ACCORD medical research ethics committee, AMREC (ACCORD is the Academic and Clinical Central

Office for Research and Development, a joint office of the University of Edinburgh and NHS Lothian - Ethics approval reference 15-HV-016). The Edinburgh Brain Bank is a Medical Research Council funded facility with research ethics committee (REC) approval (11/ES/0022). Tissue from 14 donors was used for this study and their details are found in Table S1.

Consent for publication: Not applicable.

Competing interests: CAFvA received honoraria from serving on the scientific advisory board of Nutricia GmbH (2014) and Hong Kong University Research Council (2014) and has received funding for travel and speaker honoraria from Nutricia GmbH (2014), Novartis Pharma GmbH (2011), Lilly Deutschland GmbH (2013), Desitin Arzneimittel GmbH (2014) and Dr. Willmar Schwabe GmbH & Co. KG (2014) as well as research support from Roche Diagnostics GmbH (2013–2015), Biologische Heilmittel Heel GmbH (2012) and ViaMed GmbH (2011–2014).

HR and KSK are employees of Boehringer Ingelheim Pharma GmbH & Co KG.

All authors report no conflict of interest.

Funding: This work was supported by the Boehringer Ingelheim Ulm University BioCenter (BIU) project N7. Further support was provided by Alzheimer's Research UK, the European Research Council, a University of Edinburgh Wellcome Trust Institutional Strategic Support Fund, the UK Dementia Research Institute and an anonymous donor.

Authors contributions: Study concept and design: CAFvA, HR, RH, BvE, DS, CS; acquisition of data: RH, FW, PB, RJJ, PW; analysis and interpretation of data: RH, BvE, LL, HK, CAFvA; drafting of the manuscript: RH, CAFvA, HR; critical revision of the manuscript for important intellectual content: CAFvA, HR, TMB, KSK, TSJ, HK, KF, CP

Acknowledgements: The authors thank Ulrike Formentini (Ulm University) and Dirk Gester (Boehringer Ingelheim) for their help in preparation of primary hippocampal neurons and FLIPR-imaging and Renate Kunz (Central facility for electron microscopy Ulm University) for preparation of EM samples. The authors also thank the MRC Edinburgh Brain and Tissue Bank as well as all donors and their families.

Authors' information: ¹Department of Neurology, Ulm University, Ulm, Germany; ²Boehringer Ingelheim Pharma GmbH & Co KG, Dept. of CNS Diseases Research, Biberach, Germany; ³Boehringer Ingelheim Pharma GmbH & Co KG, Dept. of Drug Discovery Sciences, Biberach, Germany; ⁴Institute for Anatomy and Cell Biology, Ulm University, Ulm, Germany; ⁵UK Dementia Research Institute, The University of Edinburgh, Edinburgh, UK; ⁶Institute of

Medical Systems Biology, Ulm University, Ulm, Germany; ⁷Central Facility for Electron
Microscopy, Ulm University, Ulm, Germany; ⁸Department of Anesthesiology, Ulm University,
Ulm, Germany

References

Bell, K.F., Zheng, L., Fahrenholz, F., Cuello, A.C., 2008. ADAM-10 over-expression increases
cortical synaptogenesis. *Neurobiol Aging* 29, 554-565.
Beyer, A.S., von Einem, B., Schwanzar, D., Keller, I.E., Hellrung, A., Thal, D.R., Ingelsson,
M., Makarova, A., Deng, M., Chhabra, E.S., Pröpper, C., Böckers, T.M., Hyman, B.T., von
Arnim, C.A., 2012. Engulfment adapter PTB domain containing 1 interacts with and affects
processing of the amyloid- β precursor protein. *Neurobiol Aging* 33, 732-743.
Burnham, K.P., Anderson, D.R., 2002. *Model Selection and Multimodel Inference*. Springer,
New York.

792 Chasseigneaux, S., Allinquant, B., 2012. Functions of A β , sAPP α and sAPP β : similarities and
793 differences. *J Neurochem* 120 Suppl 1, 99-108.

794 Chasseigneaux, S., Dinc, L., Rose, C., Chabret, C., Couplier, F., Topilko, P., Mauger, G.,
795 Allinquant, B., 2011. Secreted amyloid precursor protein β and secreted amyloid precursor
796 protein α induce axon outgrowth in vitro through Egr1 signaling pathway. *PLoS One* 6, e16301.

797 Claassen, A.M., Guévremont, D., Mason-Parker, S.E., Bourne, K., Tate, W.P., Abraham, W.C.,
798 Williams, J.M., 2009. Secreted amyloid precursor protein-alpha upregulates synaptic protein
799 synthesis by a protein kinase G-dependent mechanism. *Neurosci Lett* 460, 92-96.

800 Colciaghi, F., Marcello, E., Borroni, B., Zimmermann, M., Caltagirone, C., Cattabeni, F.,
801 Padovani, A., Di Luca, M., 2004. Platelet APP, ADAM 10 and BACE alterations in the early
802 stages of Alzheimer disease. *Neurology* 62, 498-501.

803 Copanaki, E., Chang, S., Vlachos, A., Tschäpe, J.A., Müller, U.C., Kögel, D., Deller, T., 2010.
804 sAPP α antagonizes dendritic degeneration and neuron death triggered by proteasomal
805 stress. *Mol Cell Neurosci* 44, 386-393.

806 Cuchillo-Ibañez, I., Lopez-Font, I., Boix-Amorós, A., Brinkmalm, G., Blennow, K.,
807 Molinuevo, J.L., Sáez-Valero, J., 2015. Heteromers of amyloid precursor protein in
808 cerebrospinal fluid. *Mol Neurodegener* 10, 2.

809 Dotti, C.G., Sullivan, C.A., Banker, G.A., 1988. The establishment of polarity by hippocampal
810 neurons in culture. *J Neurosci* 8, 1454-1468.

811 Dünkler, A., Rösler, R., Kestler, H.A., Moreno-Andrés, D., Johnsson, N., 2015. SPLIFF: A
812 Single-Cell Method to Map Protein-Protein Interactions in Time and Space. *Methods Mol Biol*
813 1346, 151-168.

814 El-Ansary, A., Al-Ayadhi, L., 2014. GABAergic/glutamatergic imbalance relative to excessive
815 neuroinflammation in autism spectrum disorders. *J Neuroinflammation* 11, 189.

816 Fol, R., Braudeau, J., Ludewig, S., Abel, T., Weyer, S.W., Roederer, J.P., Brod, F., Audrain,
817 M., Bemelmans, A.P., Buchholz, C.J., Korte, M., Cartier, N., Müller, U.C., 2015. Viral gene
818 transfer of APPs α rescues synaptic failure in an Alzheimer's disease mouse model. *Acta*
819 *Neuropathol*.

820 Friedrich, M.W., Aramuni, G., Mank, M., Mackinnon, J.A., Griesbeck, O., 2010. Imaging
821 CREB activation in living cells. *J Biol Chem* 285, 23285-23295.

822 Furukawa, K., Barger, S.W., Blalock, E.M., Mattson, M.P., 1996a. Activation of K⁺ channels
823 and suppression of neuronal activity by secreted beta-amyloid-precursor protein. *Nature* 379,
824 74-78.

825 Furukawa, K., Mattson, M.P., 1998. Secreted amyloid precursor protein alpha selectively
826 suppresses N-methyl-D-aspartate currents in hippocampal neurons: involvement of cyclic
827 GMP. *Neuroscience* 83, 429-438.

828 Furukawa, K., Sopher, B.L., Rydel, R.E., Begley, J.G., Pham, D.G., Martin, G.M., Fox, M.,
829 Mattson, M.P., 1996b. Increased activity-regulating and neuroprotective efficacy of alpha-
830 secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding
831 domain. *J Neurochem* 67, 1882-1896.

832 Goetz, A.K., Scheffler, B., Chen, H.X., Wang, S., Suslov, O., Xiang, H., Brüstle, O., Roper,
833 S.N., Steindler, D.A., 2006. Temporally restricted substrate interactions direct fate and
834 specification of neural precursors derived from embryonic stem cells. *Proc Natl Acad Sci U S*
835 *A* 103, 11063-11068.

836 Goodman, Y., Mattson, M.P., 1994. Secreted forms of beta-amyloid precursor protein protect
837 hippocampal neurons against amyloid beta-peptide-induced oxidative injury. *Exp Neurol* 128,
838 1-12.

839 Grabrucker, A., Vaida, B., Bockmann, J., Boeckers, T.M., 2009. Synaptogenesis of
840 hippocampal neurons in primary cell culture. *Cell Tissue Res* 338, 333-341.

841 Grabrucker, A.M., Knight, M.J., Proepper, C., Bockmann, J., Joubert, M., Rowan, M.,
842 Nienhaus, G.U., Garner, C.C., Bowie, J.U., Kreutz, M.R., Gundelfinger, E.D., Boeckers, T.M.,

843 2011. Concerted action of zinc and ProSAP/Shank in synaptogenesis and synapse maturation.
 844 EMBO J 30, 569-581.

845 Götz, J., Schonrock, N., Vissel, B., Ittner, L.M., 2009. Alzheimer's disease selective
 846 vulnerability and modeling in transgenic mice. J Alzheimers Dis 18, 243-251.

847 Hasebe, N., Fujita, Y., Ueno, M., Yoshimura, K., Fujino, Y., Yamashita, T., 2013. Soluble β -
 848 amyloid Precursor Protein Alpha binds to p75 neurotrophin receptor to promote neurite
 849 outgrowth. PLoS One 8, e82321.

850 Hick, M., Herrmann, U., Weyer, S.W., Mallm, J.P., Tschäpe, J.A., Borgers, M., Mercken, M.,
 851 Roth, F.C., Draguhn, A., Slomianka, L., Wolfer, D.P., Korte, M., Müller, U.C., 2015. Acute
 852 function of secreted amyloid precursor protein fragment APPs α in synaptic plasticity. Acta
 853 Neuropathol 129, 21-37.

854 Hires, S.A., Zhu, Y., Tsien, R.Y., 2008. Optical measurement of synaptic glutamate spillover
 855 and reuptake by linker optimized glutamate-sensitive fluorescent reporters. Proc Natl Acad Sci
 856 U S A 105, 4411-4416.

857 Hock, C., Golombowski, S., Müller-Spahn, F., Naser, W., Beyreuther, K., Mönning, U.,
 858 Schenk, D., Vigo-Pelfrey, C., Bush, A.M., Moir, R., Tanzi, R.E., Growdon, J.H., Nitsch, R.M.,
 859 1998. Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in
 860 Alzheimer's disease and major depression - inverse correlation with dementia severity. Eur
 861 Neurol 39, 111-118.

862 Holsinger, R.M., McLean, C.A., Collins, S.J., Masters, C.L., Evin, G., 2004. Increased beta-
 863 Secretase activity in cerebrospinal fluid of Alzheimer's disease subjects. Ann Neurol 55, 898-
 864 899.

865 Janssens, N., Lesage, A.S., 2001. Glutamate receptor subunit expression in primary neuronal
 866 and secondary glial cultures. J Neurochem 77, 1457-1474.

867 Ji, Y., Lu, Y., Yang, F., Shen, W., Tang, T.T., Feng, L., Duan, S., Lu, B., 2010. Acute and
 868 gradual increases in BDNF concentration elicit distinct signaling and functions in neurons. Nat
 869 Neurosci 13, 302-309.

870 Johnson-Venkatesh, E.M., Umemori, H., 2010. Secreted factors as synaptic organizers. Eur J
 871 Neurosci 32, 181-190.

872 Kaech, S., Banker, G., 2006. Culturing hippocampal neurons. Nat Protoc 1, 2406-2415.

873 Kennedy, M.E., Stamford, A.W., Chen, X., Cox, K., Cumming, J.N., Dockendorf, M.F., Egan,
 874 M., Ereshefsky, L., Hodgson, R.A., Hyde, L.A., Jhee, S., Kleijn, H.J., Kuvelkar, R., Li, W.,
 875 Mattson, B.A., Mei, H., Palcza, J., Scott, J.D., Tanen, M., Troyer, M.D., Tseng, J.L., Stone,
 876 J.A., Parker, E.M., Forman, M.S., 2016. The BACE1 inhibitor verubecestat (MK-8931) reduces
 877 CNS β -amyloid in animal models and in Alzheimer's disease patients. Sci Transl Med 8,
 878 363ra150.

879 Klarenbeek, J., Goedhart, J., van Batenburg, A., Groenewald, D., Jalink, K., 2015. Fourth-
 880 generation epac-based FRET sensors for cAMP feature exceptional brightness, photostability
 881 and dynamic range: characterization of dedicated sensors for FLIM, for ratiometry and with
 882 high affinity. PLoS One 10, e0122513.

883 Lannfelt, L., Basun, H., Wahlund, L.O., Rowe, B.A., Wagner, S.L., 1995. Decreased alpha-
 884 secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's disease. Nat
 885 Med 1, 829-832.

886 Lazarov, O., Demars, M.P., 2012. All in the Family: How the APPs Regulate Neurogenesis.
 887 Front Neurosci 6, 81.

888 Lazarov, O., Marr, R.A., 2010. Neurogenesis and Alzheimer's disease: at the crossroads. Exp
 889 Neurol 223, 267-281.

890 Lomax, R.G., Hahs-Vaughn, D.L., 2012. Statistical Concepts: A
 891 Second Course. Routledge Chapman & Hall, New York.

892 Luján, R., Shigemoto, R., López-Bendito, G., 2005. Glutamate and GABA receptor signalling
 893 in the developing brain. Neuroscience 130, 567-580.

894 Mattson, M.P., Cheng, B., Culwell, A.R., Esch, F.S., Lieberburg, I., Rydel, R.E., 1993.
895 Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of
896 the beta-amyloid precursor protein. *Neuron* 10, 243-254.

897 Motulsky, H.J., Ransnas, L.A., 1987. Fitting curves to data using nonlinear regression: a
898 practical and nonmathematical review. *FASEB J* 1, 365-374.

899 Nicolas, M., Hassan, B.A., 2014. Amyloid precursor protein and neural development.
900 *Development* 141, 2543-2548.

901 Nikolaev, A., McLaughlin, T., O'Leary, D.D., Tessier-Lavigne, M., 2009. APP binds DR6 to
902 trigger axon pruning and neuron death via distinct caspases. *Nature* 457, 981-989.

903 Palmert, M.R., Usiak, M., Mayeux, R., Raskind, M., Tourtellotte, W.W., Younkin, S.G., 1990.
904 Soluble derivatives of the beta amyloid protein precursor in cerebrospinal fluid: alterations in
905 normal aging and in Alzheimer's disease. *Neurology* 40, 1028-1034.

906 Peters-Libeu, C., Campagna, J., Mitsumori, M., Poksay, K.S., Spilman, P., Sabogal, A.,
907 Bredesen, D.E., John, V., 2015. sA β PP α is a Potent Endogenous Inhibitor of BACE1. *J*
908 *Alzheimers Dis* 47, 545-555.

909 Prox, J., Rittger, A., Saftig, P., 2012. Physiological functions of the amyloid precursor protein
910 secretases ADAM10, BACE1, and presenilin. *Exp Brain Res* 217, 331-341.

911 Ray, B., Long, J.M., Sokol, D.K., Lahiri, D.K., 2011. Increased secreted amyloid precursor
912 protein- α (sAPP α) in severe autism: proposal of a specific, anabolic pathway and putative
913 biomarker. *PLoS One* 6, e20405.

914 Ring, S., Weyer, S.W., Kilian, S.B., Waldron, E., Pietrzik, C.U., Filippov, M.A., Herms, J.,
915 Buchholz, C., Eckman, C.B., Korte, M., Wolfer, D.P., Müller, U.C., 2007. The secreted beta-
916 amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical,
917 behavioral, and electrophysiological abnormalities of APP-deficient mice. *J Neurosci* 27, 7817-
918 7826.

919 Roch, J.M., Masliah, E., Roch-Levecq, A.C., Sundsmo, M.P., Otero, D.A., Veinbergs, I.,
920 Saitoh, T., 1994. Increase of synaptic density and memory retention by a peptide representing
921 the trophic domain of the amyloid beta/A4 protein precursor. *Proc Natl Acad Sci U S A* 91,
922 7450-7454.

923 Rohe, M., Carlo, A.S., Breyhan, H., Sporbert, A., Miltz, D., Schmidt, V., Wozny, C., Harmeier,
924 A., Erdmann, B., Bales, K.R., Wolf, S., Kempermann, G., Paul, S.M., Schmitz, D., Bayer, T.A.,
925 Willnow, T.E., Andersen, O.M., 2008. Sortilin-related receptor with A-type repeats (SORLA)
926 affects the amyloid precursor protein-dependent stimulation of ERK signaling and adult
927 neurogenesis. *J Biol Chem* 283, 14826-14834.

928 Ryan, M.M., Morris, G.P., Mockett, B.G., Bourne, K., Abraham, W.C., Tate, W.P., Williams,
929 J.M., 2013. Time-dependent changes in gene expression induced by secreted amyloid precursor
930 protein-alpha in the rat hippocampus. *BMC Genomics* 14, 376.

931 Selkoe, D.J., Hardy, J., 2016. The amyloid hypothesis of Alzheimer's disease at 25 years.
932 *EMBO Mol Med*.

933 SHOLL, D.A., 1953. Dendritic organization in the neurons of the visual and motor cortices of
934 the cat. *J Anat* 87, 387-406.

935 Singh, B., Henneberger, C., Betances, D., Arevalo, M.A., Rodríguez-Tébar, A., Meier, J.C.,
936 Grantyn, R., 2006. Altered balance of glutamatergic/GABAergic synaptic input and associated
937 changes in dendrite morphology after BDNF expression in BDNF-deficient hippocampal
938 neurons. *J Neurosci* 26, 7189-7200.

939 Suh, J., Choi, S.H., Romano, D.M., Gannon, M.A., Lesinski, A.N., Kim, D.Y., Tanzi, R.E.,
940 2013. ADAM10 missense mutations potentiate β -amyloid accumulation by impairing
941 prodomain chaperone function. *Neuron* 80, 385-401.

942 Tai, H.C., Serrano-Pozo, A., Hashimoto, T., Frosch, M.P., Spires-Jones, T.L., Hyman, B.T.,
943 2012. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease

is associated with dysfunction of the ubiquitin-proteasome system. *Am J Pathol* 181, 1426-1435.

Takano, T., Xu, C., Funahashi, Y., Namba, T., Kaibuchi, K., 2015. Neuronal polarization. *Development* 142, 2088-2093.

Taylor, C.J., Ireland, D.R., Ballagh, I., Bourne, K., Marechal, N.M., Turner, P.R., Bilkey, D.K., Tate, W.P., Abraham, W.C., 2008. Endogenous secreted amyloid precursor protein- α regulates hippocampal NMDA receptor function, long-term potentiation and spatial memory. *Neurobiol Dis* 31, 250-260.

Wang, B., Wang, Z., Sun, L., Yang, L., Li, H., Cole, A.L., Rodriguez-Rivera, J., Lu, H.C., Zheng, H., 2014. The amyloid precursor protein controls adult hippocampal neurogenesis through GABAergic interneurons. *J Neurosci* 34, 13314-13325.

Wang, S.S., Held, R.G., Wong, M.Y., Liu, C., Karakhanyan, A., Kaeser, P.S., 2016. Fusion Competent Synaptic Vesicles Persist upon Active Zone Disruption and Loss of Vesicle Docking. *Neuron* 91, 777-791.

Young-Pearse, T.L., Chen, A.C., Chang, R., Marquez, C., Selkoe, D.J., 2008. Secreted APP regulates the function of full-length APP in neurite outgrowth through interaction with integrin β 1. *Neural Dev* 3, 15.

Zetterberg, H., Andreasson, U., Hansson, O., Wu, G., Sankaranarayanan, S., Andersson, M.E., Buchhave, P., Londos, E., Umek, R.M., Minthon, L., Simon, A.J., Blennow, K., 2008. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. *Arch Neurol* 65, 1102-1107.

Zhang, X., Odom, D.T., Koo, S.H., Conkright, M.D., Canettieri, G., Best, J., Chen, H., Jenner, R., Herbolsheimer, E., Jacobsen, E., Kadam, S., Ecker, J.R., Emerson, B., Hogenesch, J.B., Unterman, T., Young, R.A., Montminy, M., 2005. Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. *Proc Natl Acad Sci U S A* 102, 4459-4464.

Figure Legends

Figure 1: Morphological analysis of primary hippocampal neurons upon His-EGFP-sAPP treatment at DIV4 and DIV7. DIV2 PHNs were treated with 100nM His-EGFP-sAPP α or His-EGFP-sAPP β and fixed and stained at DIV4 (A-C) or DIV7 (D-H). A) Boxplots comparing primary axon lengths of PHNs treated with control peptide and His-EGFP-sAPP treated neurons. Statistical analysis revealed that there is no statistically significant difference between

His-EGFP-control and His-EGFP-sAPP treated groups. $p < 0.05$, One-Way ANOVA, Kruskal-Wallis Test. B) Boxplots comparing entire neurite lengths of PHNs treated with His-EGFP-control peptide and His-EGFP-sAPP treated neurons. Statistical analysis revealed that there is no statistically significant difference between control and His-EGFP-sAPP treated groups. $p < 0.05$, One-Way ANOVA, Kruskal-Wallis Test. C) Boxplots comparing neurite numbers of PHNs treated with His-EGFP-control peptide and His-EGFP-sAPP treated neurons. Statistical analysis revealed that there is no statistically significant difference between His-EGFP-control and His-EGFP-sAPP treated groups. $p < 0.05$, One-Way ANOVA, Kruskal-Wallis Test. D) Boxplots comparing primary axon lengths of PHNs treated with His-EGFP-control peptide and His-EGFP-sAPP treated neurons. Statistical analysis revealed that there is a statistically significant difference between His-EGFP-control and His-EGFP-sAPP α treated group. $p < 0.05$, One-Way ANOVA, Kruskal-Wallis test. E) Boxplots comparing entire neurite lengths of PHNs treated with His-EGFP-control peptide and His-EGFP-sAPP treated neurons. Statistical analysis revealed that there is a statistically significant difference between His-EGFP-control and His-EGFP-sAPP α as well as His-EGFP-sAPP β treated groups. $p < 0.05$, One-Way ANOVA, Kruskal-Wallis Test. F) Boxplots comparing neurite numbers of PHNs treated with His-EGFP-control peptide and His-EGFP-sAPP treated neurons. Statistical analysis revealed that there is a statistically significant difference between His-EGFP-control and His-EGFP-sAPP α as well as His-EGFP-sAPP β treated groups. $p < 0.05$, One-Way ANOVA, Kruskal-Wallis Test. G) Representative diagram view of sholl analysis of dendritic complexity from PHNs. H) Sholl analysis of dendritic complexity of PHNs treated with His-EGFP-control peptide or His-EGFP-sAPP α (upper plot) / His-EGFP-sAPP β (lower plot). Each group comprises N=60 neurons from 3 independent cultures (~180 neurons in total for Fig. 1 A-F and ~60 neurons in total for Fig. 1 H). Asterisks indicate a statistically significant difference between His-EGFP-control and His-EGFP-sAPP treated groups. $*p < 0.05$, $**p < 0.01$, $***p < 0.001$, position wise Wilcoxon-test (26 tests, Bonferroni correction for multiple testing). Overall differences of curves are tested with the CuCompare software.

Figure 2: Advanced glutamatergic architecture upon mCherry-sAPP overexpression. PHNs were lentiviral transduced at 2DIV with either mCherry-control, mCherry-sAPP α or mCherry-sAPP β virus. A) Exemplary hippocampal neuron picture of mCherry-control, mCherry-sAPP α and mCherry-sAPP β transduced neurons. Neurons were fixed at DIV14 and stained with Homer1 (red) and Bassoon (green) antibodies. Colocalizations indicating a mature glutamatergic synapse were counted and normalized to 10 μ m dendrite length. Scale bar: 10 μ m B) Statistical analysis revealed a significant higher number of Homer1/Bassoon colocalizations

upon mCherry-sAPP α as well as mCherry-sAPP β overexpression. $p < 0.0001$, Kruskal-Wallis test. 180 neurons from 3 independent cultures were analyzed for each condition. C) Analysis of Homer1/Bassoon colocalizations after mCherry-control, mCherry-sAPP α or mCherry-sAPP β overexpression (plotted according to cumulative frequency) revealed that mCherry-sAPP α as well as mCherry-sAPP β lead to a homogenous rightward shift in the frequency curve. D) Exemplary images of synaptic ultrastructure of mCherry-control, mCherry-sAPP α and mCherry-sAPP β overexpressing hippocampal DIV14 neurons obtained by transmission electron microscopy. Asterisks indicate the postsynaptic density. Scale bar: 100 nm. E) Statistical analysis revealed a significant increase of postsynaptic density layer thickness of mCherry-sAPP α exposed neurons. $p < 0.0001$, Kruskal-Wallis test. 60 PSDs from three independent cultures were analyzed for each condition F) Analysis of layer thicknesses of PSDs after mCherry-control, mCherry-sAPP α or mCherry-sAPP β overexpression (plotted according to cumulative frequency) revealed that mCherry-sAPP α lead to a rightward shift in the frequency curve.

Figure 3: Glutamate sensitivity of DIV7 PHNs is increased upon His-EGFP-sAPP treatment. A) 15 minutes pre-Incubation of PHNs with both His-EGFP-sAPP α and His-EGFP-sAPP β (1 nM) increase the Ca²⁺-influx in DIV14 PHNs upon glutamate (10 μ M) stimulation. $n=3$, $N=18$ wells; $p < 0.05$, Two-Way ANOVA, Dunnett's post hoc test. B-C) DIV2 PHNs were treated with 100nM His-EGFP-sAPP α or His-EGFP-sAPP β and stimulated with 10 μ M glutamate at DIV4, DIV7 or DIV14 respectively. To determine phospho ERK2 (lower bands) and phospho CREB1 levels Western blots were quantified by densitometric analysis. p-ERK2 levels were normalized to t-ERK2 levels and p-CREB1 levels were normalized to total levels of CREB1 B) Relative protein levels of p-ERK2 were significantly increased upon His-EGFP-sAPP α treatment at DIV7. $p = 0.02$ Kruskal-Wallis Test. $n=3$ independent cultures. p-ERK2/t-ERK2 ratio was not significantly altered upon His-EGFP-sAPP treatment and glutamate stimulation at DIV4 and DIV14. C) Relative protein levels of p-CREB1 were significantly increased upon His-EGFP-sAPP α treatment and increased by trend after His-EGFP-sAPP β treatment at DIV7. His-EGFP-sAPP α vs His-EGFP-control: $p = 0.001$, His-EGFP-sAPP β vs. His-EGFP-control: $p = 0.056$. Kruskal-Wallis test. $n=3$ independent cultures, at least three technical replicates per culture. P-CREB1/t-CREB1 ratio was not significantly altered upon His-EGFP-sAPP treatment and glutamate stimulation at DIV4 and DIV14.

Figure 4: mCherry-sAPP overexpression lead to advanced glutamatergic architecture at DIV14 comparable to control treated DIV21 neurons but it suppresses the formation of

GABAergic inputs. PHNs were lentiviral transduced at DIV2 with either mCherry-control, mCherry-sAPP α or mCherry-sAPP β virus. mCherry-sAPP treated neurons were fixed and stained at DIV14. mCherry-Control treated neurons were fixed and stained and DIV14 and DIV21. A) Exemplary PHN dendrites after overexpression of control construct and fixed at DIV14 and DIV21 and overexpression of mCherry-sAPP α or mCherry-sAPP β fixed at DIV14. Presynapses were stained by VGlut1 antibodies. B) Statistical analysis revealed a significant higher number VGLUT1 positive puncta (presynaptic marker) upon mCherry-sAPP α as well as mCherry-sAPP β overexpression. PHNs overexpressing the control construct $p < 0.0001$, Kruskal-Wallis test. 60 neurons from 3 independent cultures were analyzed for each condition. C) Exemplary PHN dendrites after overexpression of control construct and fixed at DIV14 and DIV21 and overexpression of mCherry-sAPP α or mCherry-sAPP β fixed at DIV14. Presynapses were stained by VGAT antibodies. B) Statistical analysis revealed a significant higher number VGAT positive puncta (presynaptic marker) upon mCherry-sAPP α as well as mCherry-sAPP β overexpression. PHNs overexpressing the control construct $p < 0.0001$, Kruskal-Wallis test. 60 neurons from 3 independent cultures were analyzed for each condition. E) The E/I ratio was calculated by dividing the average number of VGlut1 pos. puncta by the average number of VGAT pos. puncta along 10 μ m dendrite length. The foldchange over control was calculated and plotted. E/I ratio at DIV14 of mCherry-sAPP α as well as mCherry-sAPP β treated neurons is significantly increased compared to mCherry-control treated neurons. When comparing DIV14 control treated neurons with DIV21 mCherry-control treated neurons, no significant change was observed. $p < 0.0001$, One-Way ANOVA, Kruskal-Wallis test, Dunn's post-hoc test. F) Schematic diagram for proposed functions of sAPPs in modulating glutamatergic development in PHNs.

Figure 5: sAPP α levels are significantly reduced in brain homogenates of AD patients. A) Qualitative Western blot analysis of 14 human brains (seven control and seven AD brains) revealed that sAPP α is detectable by a specific sAPP α antibodies in human brain homogenates and that sAPP α levels are significantly lower in AD brain homogenates compared to control subjects. $p = 0.007$, Mann-Whitney U -test. B) Enrichment of synaptic fraction showed that sAPP α are detectable in the corresponding synaptic pellets and a trend of reduced sAPP α levels in AD synaptoneurosomes compared to control subjects was observed. $p = 0.128$, Mann-Whitney U -test. Western blots were quantified by densitometric analysis.

Figure S1: Qualitative analysis of recombinant His-EGFP-sAPPs produced in Flp-In-HEK293 cells and by using a lentiviral system reveals no cross contamination between

sAPP α and sAPP β production A) Simply blue safe stained SDS-PAGE gel showing no side bands in His-EGFP-sAPP α and His-EGFP-sAPP β elutions (His purification from HEK293 cell supernatant). B) Corresponding Western Blot to stained SDS-PAGE gel. The upper blot shows bands detected with an anti β -Amyloid antibody (6e10). In the His-EGFP-sAPP α elution lane a band at ~120 kDa can be detected, whereas no band is visible in the His-EGFP-sAPP β elution lane. The lower blot shows bands detected with an antibody directed against the n-terminus of APP (22c11). There are bands at ~120 kDa visible in the His-EGFP-sAPP α and His-EGFP-sAPP β elution lane. C) Western Blots showing the supernatant of DIV14 PHNs upon sAPP lentiviral transduction at DIV2. The left blot shows a band detected with an anti β -Amyloid antibody (6e10) in the supernatant of mCherry-sAPP α transduced neurons. The right blot shows bands detected with an antibody directed against the n-terminus of APP (22c11) in the supernatant of mCherry-sAPP α and mCherry-sAPP β transduced neurons. No band is visible in the supernatant of mCherry-pUltra hot transduced neurons. D) Schematic illustration of specificity of the used antibodies for the qualification of recombinant sAPP production.

Figure S2: Exemplary images of DIV4 and DIV7 PHNs used for morphometric analysis upon control peptide and His-EGFP-sAPP treatment. A-C) PHNs were treated with control peptide or His-EGFP-sAPPs at DIV2 and stained at DIV4 with an anti-beta-III-tubulin antibody to assess the morphology of His-EGFP-control (A), His-EGFP-sAPP α (B) and His-EGFP-sAPP β (C) treatment. D-F) PHNs were treated with His-EGFP-control peptide or His-EGFP-sAPPs at DIV2 and stained at DIV7 with anti-tau (red) and anti-MAP2 antibodies (green) to assess the morphology of His-EGFP-control (D), His-EGFP-sAPP α (E) and His-EGFP-sAPP β (F) treatment. Scale bars: 100 μ m.

Figure S3: His-EGFP-sAPP α increases CREB-1 phosphorylation in SH-SY5Y cells in a time-dependent manner. A) Ratiometric analysis of Venus and mTurquoise fluorescence intensities shows a significant increase of CREB-1 phosphorylation in SH-SY5Y cells upon His-EGFP-sAPP α pre-treatment (1nM). CREB phosphorylation was determined by the CREB-phosphorylation biosensor ICAP. Cells were stimulated with 10 μ M glutamate and Venus/mTurquoise intensities ratios were recorded after 5, 12, 19, 24, 30, 35, 40, 45, 50, 55 and 60 minutes. B) Ratiometric analysis of Venus and mTurquoise fluorescence intensities shows no alterations of CREB-1 phosphorylation in SH-SY5Y cells upon His-EGFP-sAPP β pre-treatment (1nM). CREB phosphorylation was determined by the CREB-phosphorylation biosensor ICAP. Cells were stimulated with 10 μ M glutamate and Venus/mTurquoise intensities ratios were recorded after 5, 12, 19, 24, 30, 35, 40, 45, 50, 55 and 60 minutes. His-EGFP-control

group (N=21), His-EGFP-sAPP α (N=11), His-EGFP-sAPP β (N=21). Asterisks indicate a statistically significant difference between His-EGFP-control and His-EGFP-sAPP α treated groups. $*p < 0.05$, $**p < 0.01$, $***p < 0.001$, position wise Wilcoxon-test (12 tests, Bonferroni correction for multiple testing). Overall differences of curves are tested with the CuCompare software.

Figure S4: **sAPP β is not detectable in human brain homogenates.** Western blot showing sAPP β cleavage fragments. Full length sAPP β at 90-100 kDA molecular weight is not detectable.

Table S1: **Patient demographic data**

Edinburgh brain bank number	BBN NUMBER	Gender	diagnosis	Age[y]
SD001/16	28406	M	control	79
SD017/16	28793	F	control	79
SD018/16	28794	F	control	79
SD024/15	26495	M	control	78
SD051/15	19597	M	control	79
SD032/13	16425	M	control	61
SD063/13	19686	F	control	77
SD049/14	24322	M	AD	80
SD055/14	24526	M	AD	79
SD056/14	24527	M	AD	81
SD007/15	25056	M	AD	72
SD014/15	25739	F	AD	85
SD040/15	26718	M	AD	78
SD005/16	28410	F	AD	62

M = male, F = female

Supplementary Methods:

Measurement of the time-dependent phosphorylation of CREB1

To measure the time-dependent phosphorylation of CREB1 SH-SY5Y cells were transfected with a FRET based indicators of phosphorylation for CREB1 (pNLS- mTurquoise2 Δ -11AA-ICAP- td_cp173Venus(d)_188_NES-pUltraHot) (Friedrich et al., 2010; Klarenbeek et al., 2015). On the day before the transfection SH-SY5Y cells were seeded onto a 96 Well Black Clear Flat Bottom TC-Treated Microplate (Corning, New York, USA) at a density of 4×10^4

1140 cells per well. The cells were incubated overnight at 37 ° C and 5% CO₂ in 10 ml DMEM plus
1141 10 % fetal calf serum and 1 % Penicillin with Streptomycin and are transfected the next morning
1142 according to the manufacturer's instructions of the LTX & Plus Reagent Kit. After another 24
1143 hours of incubation under the same conditions the cells were used for measurements in the
1144 microplate reader. To carry out the experiments the medium must be replaced by a clear wash
1145 buffer (for buffer composition see FLIPR-analysis part in Material & Methods section) which
1146 does not influence the fluorescence intensity to be measured. The 96 well plate was then placed
1147 in the to 37 ° C preheated Clariostar microplate reader (BMG Labtech, Ortenberg, Germany).
1148 In the reader, the cells were excited with a wavelength of 430 nm and the emission is measured
1149 at 480 nm and 550 nm. The first emission wavelength corresponds to the range in which
1150 mTurquoise2Δ emits, the second wavelength is slightly above the emission of the Venus
1151 fluorophore (530 nm) to avoid a blend with the emitting light of turquoise. Other important
1152 measurement settings are: focal height 3.8 mm, bottom reading and well scan with a 5x5 matrix.
1153 First the fluorescence intensities of the untreated cells were measured. Subsequently, the cells
1154 were treated with glutamate (final concentration 10 μM) and the fluorescence intensity was
1155 measured again at 5, 12, 19, 24, 30, 35, 40, 45, 50, 55 and 60 minutes after stimulation for the
1156 measurements of CREB-activity. For the measurements, the cells were pretreated with His-
1157 EGFP-sAPPα/β / His-EGFP-control peptide (1nM) for 24 h. The analysis of the measured
1158 fluorescence intensities was performed with the Clariostar Data Analysis software (BMG
1159 Labtech, Ortenberg, Germany). For the evaluation, the fluorescence intensity of Venus
1160 (detection at 550 nm) was set in relation to the fluorescence intensity of Turquoise (detection
1161 at 480 nm), the ratio was then standardised to the fluorescence ratio of the untreated and
1162 unstimulated cells.